Efficacy of artemether and artesunate in mice infected with praziquantel non-susceptible isolate of Schistosoma japonicum

Parasitology Research

Volumn 113, Issue 3, 2014, Pages 925-931

  Wang, Wei ^a,b   Li, Tian Yu ^c   Ji, Yuan ^d   Qu, Guo Li ^a,b   Qian, Yi Li ^a,b   Li, Hong Jun ^e   Dai, Jian Rong ^a,b   Liang, You Sheng ^a,b  

^a JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

^b BEIJING HOSPITAL   (China)

^c Wuxi Children's Hospital   (China)

^d WUXI NO 2 PEOPLE S HOSPITAL   (China)

^e AFFILIATED HOSPITAL OF WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ARTEMETHER PLUS ARTESUNATE; ARTESUNATE; CREMOPHOR; PRAZIQUANTEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HELMINTHIASIS; IN VIVO STUDY; JUVENILE; MOUSE; NONHUMAN; PARASITE ISOLATION; PRIORITY JOURNAL; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS; SINGLE DRUG DOSE; WORM;

ANIMALIA; ARTESUNATE; MUS; SCHISTOSOMA JAPONICUM;

ADMINISTRATION, ORAL; ANIMALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; FEMALE; MICE; MICE, INBRED ICR; PRAZIQUANTEL; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; SCHISTOSOMICIDES;

EID: 84895510569     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-013-3724-5     Document Type: Article

References (68)

1. Alonso D, Muñoz J, Gascón J, Valls ME, Corachan M (2006) Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg 74:342-344
2. Aragon AD, Imani RA, Blackburn VR, Cupit PM, Melman SD, Goronga T, Webb T, Loker ES, Cunningham C (2009) Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol 164:57-65
3. Chen MG (2005) Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Acta Trop 96:168-176
4. Chen XY, Wang LY, Cai JM, Zhou XN, Zheng J, Guo JG, Wu XH, Engels D, Chen MG (2005) Schistosomiasis control in China: the impact of a 10-year World Bank Loan Project (1992-2001). Bull World Health Organ 83:43-48
5. Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96:465-469
6. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659-667
7. Engels D, Wang LY, Palmer KL (2005) Control of schistosomiasis in China. Acta Trop 96:67-68
8. Fallon PG, Doenhoff MJ (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 51:83-88
9. Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ (1995) Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 53:61-62
10. Fallon PG, Tao LF, Ismail MM, Bennett JL (1996) Schistosome resistance to praziquantel: fact or artifact? Parasitol Today 12:316-320
11. 2+ channels targets of praziquantel action? Int J Parasitol 35:1-9
12. Greenberg RM (2013) New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology 140:1534-1546
13. Harnett W (1988) The anthelmintic action of praziquantel. Parasitol Today 4:144-146
14. Hommel M (2008) The future of artemisinins: natural, synthetic or recombinant? J Biol 7:38
15. Hua HY, Liang YS, Zhang Y, Wei JF, Guo HX (2010) The sensitivity of artesunate against Schistosoma japonicum decreased after 10 years of use in China. Parasitol Res 107:873-878
16. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL (1996) Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55:214-218
17. Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA, Bennett JL (1999) Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60:932-935
18. Keiser J, Utzinger J (2012) Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18:3531-3538
19. Köhler P (2001) The biochemical basis of anthelmintic action and resistance. Int J Parasitol 31:336-345
20. Li S, Wu L, Liu Z, Hu L, Xu P, Xuan Y, Liu Y, Liu X, Fan J (1996) Studies on prophylactic effect of artesunate on schistosomiasis japonica. Chin Med J (Engl) 109:848-853
21. Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP (2005) A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop 96:184-190
22. Li SZ, Luz A, Wang XH, Xu LL, Wang Q, Qian YJ, Wu XH, Guo JG, Xia G, Wang LY, Zhou XN (2009) Schistosomiasis in China: acute infections during 2005-2008. Chin Med J (Engl) 122:1009-1014
23. Li HJ, Liang YS, Dai JR, Wang W, Qu GL, Li YZ, Xing YT, Tao YH, Qian K, Jia Y, Yang ZK, Wei JY (2011) Studies on resistance of Schistosoma to praziquantel XIV experimental comparison of susceptibility to praziquantel between PZQ-resistant isolates and PZQ-susceptible isolates of Schistosoma japonicum in stages of adult worms, miracidia and cercariae. Chin J Schisto Control 23:611-619
24. Liang YS, Dai JR, Ning A, Yu DB, Xu XJ, Zhu YC, Coles GC (2001) Susceptibility of Schistosoma japonicum to praziquantel in China. Trop Med Int Health 6:707-714
25. Liang YS, Li HJ, Dai JR et al (2011) Studies on resistance of Schistosoma to praziquantel XIII resistance of Schistosoma japonicum to praziquantel is experimentally induced in laboratory. Chin J Schisto Control 23:605-610
26. Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS (2011) Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasitol Vectors 4:201
27. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3:e504
28. Meshnick SR (2002) Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 32:1655-1660
29. Pérez del Villar L, Burguillo FJ, López-Abán J, Muro A (2012) Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One 7:e45867
30. Prociv P (1997) A case of refractory schistosomiasis. Med J Aust 166:568
31. Ru WW, Liang YS, Dai JR, Li HJ, Xu YL, Zhu YC, Xu M (2006) Studies on effect of artesunate against Schistosoma japonicum. I Susceptibility of different developmental stages of worms in mice to artesunate. Chin J Schisto Control 18:161-164
32. Seto EY, Wong BK, Lu D, Zhong B (2011) Human schistosomiasis resistance to praziquantel in China: should we be worried? Am J Trop Med Hyg 85:74-82
33. Silva IM, Thiengo R, Conceição MJ, Rey L, Lenzi HL, Pereira Filho E, Ribeiro PC (2005) Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswaldo Cruz 100:445-449
34. Spear RC, Seto EY, Carlton EJ, Liang S, Remais JV, Zhong B, Qiu D (2011) The challenge of effective surveillance in moving from low transmission to elimination of schistosomiasis in China. Int J Parasitol 41:1243-1247
35. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6:411-425
36. Stelma FF, Talla I, Sow S, Kongs A, Niang M, Polman K, Deelder AM, Gryseels B (1995) Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 53:167-170
37. Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B (1997) Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 176:304-307
38. Tchuem-Tchuenté LA, Southgate VR, Mbaye A, Engels D, Gryseels B (2001) The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal. Trans R Soc Trop Med Hyg 95:65-66
39. Tu YY (2011) The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011(17):1217-1220
40. Utzinger J, Xiao S, N'Goran EK, Bergquist R, Tanner M (2001) The potential of artemether for the control of schistosomiasis. Int J Parasitol 31:1549-1562
41. Utzinger J, Zhou XN, Chen MG, Bergquist R (2005) Conquering schistosomiasis in China: the long march. Acta Trop 96:69-96
42. Utzinger J, Bergquist R, Olveda R, Zhou XN (2010) Important helminth infections in Southeast Asia diversity, potential for control and prospects for elimination. Adv Parasitol 72:1-30
43. Wang LD, Utzinger J, Zhou XN (2008) Schistosomiasis control: experiences and lessons from China. Lancet 372:1793-1795
44. Wang LD, Chen HG, Guo JG, Zeng XJ, Hong XL, Xiong JJ, Wu XH, Wang XH, Wang LY, Xia G, Hao Y, Chin DP, Zhou XN (2009a) A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 360:121-128
45. Wang LD, Guo JG, Wu XH, Chen HG, Wang TP, Zhu SP, Zhang ZH, Steinmann P, Yang GJ, Wang SP, Wu ZD, Wang LY, Hao Y, Bergquist R, Utzinger J, Zhou XN (2009b) China's new strategy to block Schistosoma japonicum transmission: experiences and impact beyond schistosomiasis. Trop Med Int Health 14:1475-1483
46. Wang W, Dai JR, Li HJ, Shen XH, Liang YS (2010) Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China. Parasitology 137:1905-1912
47. Wang W, Dai JR, Li HJ, Shen XH, Liang YS (2012a) The sensitivity of Schistosoma japonicum to praziquantel: a field evaluation in areas with low endemicity of China. Am J Trop Med Hyg 86:834-836
48. Wang W, Wang L, Liang YS (2012b) Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 111:1871-1877
49. Wang W, Li HJ, Qu GL, Xing YT, Yang ZK, Dai JR, Liang YS (2013) Is there a reduced sensitivity of dihydroartemisinin against praziquantel-resistant Schistosoma japonicum? Parasitol Res, in press
50. Webster HK, Lehnert EK (1994) Chemistry of artemisinin: an overview. Trans R Soc Trop Med Hyg 88:S27-S29
51. Wu W, Huang Y (2013) Application of praziquantel in schistosomiasis japonica control strategies in China. Parasitol Res 112:909-915
52. Wu W, Wang W, Huang YX (2011) New insight into praziquantel against various developmental stages of schistosomes. Parasitol Res 109:1501-1507
53. Xiao SH (2005) Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins. Acta Trop 96:153-167
54. Xiao SH, Shi Z, Zhuo S, Wang C, Zhang Z, Chu B, Zheng J, Chen M (1995) Field studies on preventive effect of artemether against infection with Schistosoma japonicum. Chin J Parasitol Parasitol Dis 13:170-173
55. Xiao SH, Booth M, Tanner M (2000) The prophylactic effects of artemether against Schistosoma japonicum infections. Parasitol Today 16:122-126
56. Xiao SH, Tanner M, N'Goran EK, Utzinger J, Chollet J, Bergquist R, Chen M, Zheng J (2002) Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop 82:175-181
57. Xiao SH, Keiser J, Chen MG, Tanner M, Utzinger J (2010) Research and development of antischistosomal drugs in the People's Republic of China: a 60-year review. Adv Parasitol 73:231-295
58. Xu M, Zhang S, Li S, Wang T, Chen J, Ou N, Fang G, Wang Q, Li J, Zhang X (1999) Field application of oral artesunate for preventing Schistosoma japonicum infection. Chin J Parasitol Parasitol Dis 17:241-243
59. Yu DB, Li Y, Sleigh AC, Yu XL, Li YS, Wei WY, Liang YS, McManus DP (2001) Efficacy of praziquantel against Schistosoma japonicum: field evaluation in an area with repeated chemotherapy compared with a newly identified endemic focus in Hunan, China. Trans R Soc Trop Med Hyg 95:537-541
60. Yuan H, Jiang Q, Zhao G, He N (2002) Achievements of schistosomiasis control in China. Mem Inst Oswaldo Cruz 97:187-189
61. Zhang Z, Jiang Q (2011) Schistosomiasis elimination. Lancet Infect Dis 11:345
62. Zhao GM, Zhao Q, Jiang QW, Chen XY, Wang LY, Yuan HC (2005) Surveillance for schistosomiasis japonica in China from 2000 to 2003. Acta Trop 96:288-295
63. Zhou XN, Wang LY, Chen MG, Wu XH, Jiang QW, Chen XY, Zheng J, Utzinger J (2005) The public health significance and control of schistosomiasis in China - then and now. Acta Trop 96:97-105
64. Zhou XN, Guo JG, Wu XH, Jiang QW, Zheng J, Dang H, Wang XH, Xu J, Zhu HQ, Wu GL, Li YS, Xu XJ, Chen HG, Wang TP, Zhu YC, Qiu DC, Dong XQ, Zhao GM, Zhang SJ, Zhao NQ, Xia G, Wang LY, Zhang SQ, Lin DD, Chen MG, Hao Y (2007a) Epidemiology of schistosomiasis in the People's Republic of China, 2004. Emerg Infect Dis 13:1470-1476
65. Zhou YB, Zhao GM, Jiang QW (2007b) Effects of the praziquantel-based control of schistosomiasis japonica in China. Ann Trop Med Parasitol 101:695-703
66. Zhou XN, Bergquist R, Leonardo L, Yang GJ, Yang K, Sudomo M, Olveda R (2010) Schistosomiasis japonica control and research needs. Adv Parasitol 72:145-178
67. Zhou YB, Zheng HM, Jiang QW (2011) A diagnostic challenge for schistosomiasis japonica in China: consequences on praziquantel-based morbidity control. Parasitol Vectors 4:194
68. Zhou YB, Liang S, Jiang QW (2012) Factors impacting on progress towards elimination of transmission of schistosomiasis japonica in China. Parasitol Vectors 5:275